4 results
The effect of the dipeptide alanyl-glutamine, intravenously or enterally and perioperatively given, on postoperative insulin resistance in colon cancer patients.
PRM-151 is being developed for potential therapeutic uses to prevent, treat, and reduce fibrosis. This study will provide an initial assessment of the safety, tolerability, and pharmacokinetics (PK) of PRM-151 after administration of ascending…
PRM-151 is being developed for potential therapeutic use to prevent, treat and reduce fibrosis. This study will provide an assessment of the safety, tolerability, pharmacokinetics and pharmacodynamics of PRM-151 after administration of ascending…
To evaluate the proportion of patients indicating an overall preference via a Patient Preference Questionnaire (PPQ) for either the subcutaneous (SC) or the intravenous (IV) route of rituximab administration.